Minimizing the Burden of Influenza: New and Emerging Strategies

Steering Committee
Ruth M. Carrico, PhD, DNP, FNP-C, CIC, FSHEA, FNAP
Professor, Division of Infectious Diseases
Department of Medicine 
University of Louisville School of Medicine
Louisville, KY

Laura Gunder McClary, DHSc, PA-C
Professor
Rocky Mountain University of Health Professions
Provo, UT

Charles Vega, MD
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Executive Director
UC Irvine Program in Medical Education for the Latino Community
Santa Ana, CA
This activity is provided by Paradigm Medical Communications, LLC.      

Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.    

Target Audience
This activity has been designed to address the educational needs of Nurse Practitioners and PAs.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify appropriate candidates for antiviral therapy based on risk of influenza-related complications, in accordance with current guideline recommendations 
  • Determine the need for influenza treatment based on signs and symptoms and on accurate interpretation of appropriate diagnostic tests, when necessary
  • Develop individualized antiviral treatment plans for patients with, or at risk of, influenza that accord with the latest evidence 

Agenda

  • Introduction
  • Case Study: Does This Patient Have Influenza?
  • Case Studies: When Is Antiviral Therapy Appropriate? Which One Should I Use?
  • Q&A

PA Continuing Education
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  This activity is accredited from 9/19/20 - 9/19/21 AAPA reference number: CME-200749.

Nurse Practitioner Continuing Education
This activity is approved for 1.0 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 20094537. This activity was planned in accordance with AANP Accreditation Standards and Policies.


How to Receive Your CME Credit
To receive a CME certificate of participation, you must:

  • Create an individual registration profile at www.paradigmmc.com/867
  • Complete the pretest survey at the link provided upon registration
  • Attend the live internet activity in its entirety
  • Complete and submit the online posttest and evaluation via the link provided at the meeting.

A certificate of participation will be issued 1 to 2 weeks following the meeting.

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com or (845) 398-5949.

There is no fee required for participation in this activity.
 
Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Faculty and Steering Committee
Ruth M. Carrico, PhD, DNP, FNP-C, CIC, FSHEA, FNAP
Consulting Fees: Sanofi Pasteur
Speakers Bureau: Pfizer Inc; Sanofi Pasteur
Grant/Research Support: Dynavax Technologies; Pfizer Inc; Sanofi Pasteur

Laura Gunder McClary, DHSc, PA-C
Dr Gunder McClary has no relevant financial interests regarding the content of this activity.

Charles Vega, MD
Dr Vega has no relevant financial interests regarding the content of this activity.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.